Literature DB >> 18365074

Cytotoxicity profiles for a series of triorganophosphinegold(I) dithiocarbamates and triorganophosphinegold(I) xanthates.

Dick de Vos1, Soo Yei Ho, Edward R T Tiekink.   

Abstract

A series of triorganophosphinegold(1) dithiocarbamate (R(3)PAuS(2)CNR'(2)) and xanthate (R(3)PAuS(2)COR') complexes have been prepared and characterised spectroscopically. Based on crystallographic evidence, the molecules feature linear gold(1) geometries defined by sulphur and phosphorus donors. The complexes, along with a series of known anti-cancer agents, have been screened against a panel of seven human cancer cell lines. Uniformly, the dithiocarbamate derivatives are more active than their xanthate counterparts, with the most active complex being Et(3)PAu(S(2)CNEt(2)), and are more active than cisplatin in all cell lines screened but, not as potent as taxol.

Entities:  

Year:  2004        PMID: 18365074      PMCID: PMC2267067          DOI: 10.1155/S156536330400010X

Source DB:  PubMed          Journal:  Bioinorg Chem Appl            Impact factor:   7.778


  4 in total

Review 1.  Therapeutic potential of dithiocarbamate supported gold compounds.

Authors:  Christian K Adokoh
Journal:  RSC Adv       Date:  2020-01-16       Impact factor: 4.036

2.  Phosphinogold(I) dithiocarbamate complexes: effect of the nature of phosphine ligand on anticancer properties.

Authors:  Frankline K Keter; Ilia A Guzei; Margo Nell; Werner E van Zyl; James Darkwa
Journal:  Inorg Chem       Date:  2014-01-29       Impact factor: 5.165

3.  Crystal structure of [μ2-1,1'-bis-(di-phenyl-phos-phanyl)ferrocene-κ(2) P:P']bis-[(pyrrolidine-1-carbo-dithioato-κS)gold(I)].

Authors:  Yee Seng Tan; Edward R T Tiekink
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-09-12

4.  A triclinic polymorph of tri-cyclo-hexyl-phosphane sulfide: crystal structure and Hirshfeld surface analysis.

Authors:  Yi Jiun Tan; Chien Ing Yeo; Nathan R Halcovitch; Mukesh M Jotani; Edward R T Tiekink
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2017-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.